{"id":5623,"date":"2019-09-30T16:34:02","date_gmt":"2019-09-30T15:34:02","guid":{"rendered":"https:\/\/www.library.sath.nhs.uk\/research\/?p=5623"},"modified":"2021-04-16T12:57:39","modified_gmt":"2021-04-16T11:57:39","slug":"coronary-heart-disease-mortality-in-severe-and-non-severe-familial-hyper-cholesterolaemia-data-from-the-uk-simon-broome-fh-register-2019","status":"publish","type":"post","link":"https:\/\/www.library.sath.nhs.uk\/research\/2019\/09\/30\/coronary-heart-disease-mortality-in-severe-and-non-severe-familial-hyper-cholesterolaemia-data-from-the-uk-simon-broome-fh-register-2019\/","title":{"rendered":"Coronary heart disease mortality in severe and non-severe familial hyper-cholesterolaemia : data from the UK Simon Broome FH register (2019)"},"content":{"rendered":"<p><strong>Type of publication:<\/strong><br \/>\nConference abstract<\/p>\n<p><strong>Author(s):<\/strong><br \/>\nHumphries S.; Cooper J.; *Capps N.; Durrington P.; Jones B.; McDowell I.; Soran H.; Neil A.<\/p>\n<p><strong>Citation:<\/strong><br \/>\nAtherosclerosis; Aug 2019; vol. 287<\/p>\n<p><strong>Abstract:<\/strong><br \/>\nBackground and Aims: Background: In 2016 the International Atherosclerosis Society (IAS) proposed that patients with \"severe\" FH (SFH) should be identified since they might warrant early and more aggressive cholesterol-lowering treatment such as with PCSK9 inhibitors. SFH is diagnosed if LDL-cholesterol (LDLC) &gt;10 mmol\/L, or LDLC &gt;8.0 mmol\/L plus one high-risk feature, or LDLC &gt;5 mmol\/L plus two high-risk features. Here we compare CHD mortality in SFH and non-SFH patients in the UK Simon Broome Register since 1991, when<br \/>\nstatin use became routine.<br \/>\nMethod(s): 2929 Definite or Possible patients (51% women) aged 20-79 years recruited from 21 UK lipid clinics were followed between 1992-2016. The excess CHD standardised mortality ratio (SMR) compared to the population in England and Wales was calculated (95% Confidence intervals).<br \/>\nResult(s): (67.7%) patients met the SFH definition. Post 1991, the SMR for CHD mortality was significantly (p=0.007) higher for SFH (220(184-261) (34,134 person years, 129 deaths observed, vs 59 expected) compared to non-SFH of 144(98-203) (15,432 person years, 32 observed vs 22 expected). After adjustment for traditional risk factors, the Hazard Ratio for CHD mortality in SFH vs non-SFH was 122 (80-187) p=0.36. Applying UK guidelines for the use of PCSK9i agents, overall ~24% of those in the register are likely to be eligible, but if this were restricted to those with SFH, overall ~16% would qualify.<br \/>\nConclusion(s): CHD mortality remains elevated in treated FH, especially for SFH, emphasising the importance of optimal lipid-lowering, including the use of novel agents, and management of other risk factors<\/p>\n<p><a href=\"http:\/\/discovery.ucl.ac.uk\/10057962\/3\/Humphries%20HUK%20Humphries%20SB%20v4.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Link to full-text<\/a> [no password required]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Type of publication: Conference abstract Author(s): Humphries S.; Cooper J.; *Capps N.; Durrington P.; Jones B.; McDowell I.; Soran H.; Neil A. Citation: Atherosclerosis; Aug 2019; vol. 287 Abstract: Background and Aims: Background: In 2016 the International Atherosclerosis Society (IAS)<span class=\"ellipsis\">&hellip;<\/span><\/p>\n<div class=\"read-more\"><a href=\"https:\/\/www.library.sath.nhs.uk\/research\/2019\/09\/30\/coronary-heart-disease-mortality-in-severe-and-non-severe-familial-hyper-cholesterolaemia-data-from-the-uk-simon-broome-fh-register-2019\/\">Read more <span class=\"screen-reader-text\">Coronary heart disease mortality in severe and non-severe familial hyper-cholesterolaemia : data from the UK Simon Broome FH register (2019)<\/span><span class=\"meta-nav\"> &#8250;<\/span><\/a><\/div>\n<p><!-- end of .read-more --><\/p>\n","protected":false},"author":12,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"content-type":"","footnotes":""},"categories":[200],"tags":[832,336,997,771],"class_list":["post-5623","post","type-post","status-publish","format-standard","hentry","category-staff-publication","tag-832","tag-cardiology","tag-cardiovascular-care","tag-heart-disease"],"_links":{"self":[{"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/posts\/5623","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/comments?post=5623"}],"version-history":[{"count":2,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/posts\/5623\/revisions"}],"predecessor-version":[{"id":5641,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/posts\/5623\/revisions\/5641"}],"wp:attachment":[{"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/media?parent=5623"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/categories?post=5623"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/tags?post=5623"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}